SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 13.0% Stake in Avidity Biosciences Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 13.0% of Avidity Biosciences Inc.'s common stock as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 15,615,063.96 shares of Avidity Biosciences Inc. common stock.
• This ownership represents 13.0% of the total outstanding common stock of Avidity Biosciences Inc.
• FMR LLC holds sole voting power over 15,610,411.00 shares and sole dispositive power over 15,615,063.96 shares.
• Abigail P. Johnson holds sole dispositive power over 15,615,063.96 shares.
• This filing is Amendment No. 7 to a Schedule 13G, with the event date being March 31, 2025, and the filing date May 9, 2025.
• FMR LLC is classified as a parent holding company or control person.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or prospects. It merely reports a significant ownership stake.

Positives

• FMR LLC, a prominent investment management firm, and Abigail P. Johnson, its Chief Executive Officer, maintain a significant beneficial ownership stake of 13.0% in Avidity Biosciences Inc., indicating continued institutional interest.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of a significant ownership stake by a large asset manager in a publicly traded company. It reflects FMR LLC's investment position rather than specific industry trends or operational developments for Avidity Biosciences.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake provides transparency regarding the ownership structure and may influence investor perception of the company's stability and institutional backing.

Key Dates

Keywords

Avidity Biosciences Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing